Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Issue 5 (14th May 2020)

• Record Type: Journal Article
• Authors: Guan, Wei-jie; Liang, Wen-hua; Zhao, Yi; Liang, Heng-rui; Chen, Zi-sheng; Li, Yi-min; Liu, Xiao-qing; Chen, Ru-chong; Tang, Chun-li; Wang, Tao; Ou, Chun-quan; Li, Li; Chen, Ping-yan; Sang, Ling; Wang, Wei; Li, Jian-fu; Li, Cai-chen; Ou, Li-min; Cheng, Bo; Xiong, Shan; Ni, Zheng-yi; Xiang, Jie; Hu, Yu; Liu, Lei; Shan, Hong; Lei, Chun-liang; Peng, Yi-xiang; Wei, Li; Liu, Yong; Hu, Ya-hua; Peng, Peng; Wang, Jian-ming; Liu, Ji-yang; Chen, Zhong; Li, Gang; Zheng, Zhi-jian; Qiu, Shao-qin; Luo, Jie; Ye, Chang-jiang; Zhu, Shao-yong; Cheng, Lin-ling; Ye, Feng; Li, Shi-yue; Zheng, Jin-ping; Zhang, Nuo-fu; Zhong, Nan-shan; He, Jian-xing;
• Is Part Of: European respiratory journal. Volume 55:Issue 5(2020)
• Publication Date: 2020-05-14
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00547-2020
• Languages: English
• ISSNs: 0903-1936

Abstract

Background: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. Objective: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. Methods: We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. Results: The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities. Conclusion: Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes. The presence and number of comorbidities predict clinical outcomes of COVID-19 http://bit.ly/3b9ibw5